Daily blog desk

Source-linked Type 1 diabetes articles, generated from the live feed.

This is the public face for ongoing content: daily briefings, device safety watches, trial roundups, research watches, and evidence-label explainers. Updated from the same source pipeline that powers the feed.

Daily BriefingDevice SafetyClinical TrialsResearch WatchEditorial Policy

Daily Briefing/September 12, 2026/3 min read

September 12, 2026 Type 1 diabetes briefing: trials, device safety, and research signals

A daily Type1Cure briefing built from current official and public source pulls, with each item labeled by source, evidence class, and family relevance.

Read today's brief

A Type 1 diabetes intelligence desk with research, device, and care-planning materials.

Source-backed article

A continuous glucose monitor worn on the arm.

Device Safety

Type 1 diabetes device safety watch: latest FDA recall signals families should review

A focused safety brief from the current FDA device recall lane, prioritizing CGM, pump, insulin-delivery, glucose-monitoring, and related diabetes-device records.

September 12, 2026 / 10 sources

A diabetes education and community support setting.

Clinical Trials

Recruiting Type 1 diabetes trials watch: what changed in the current registry feed

A plain-English watchlist of current recruiting Type 1 diabetes studies surfaced from ClinicalTrials.gov, with consent-first guardrails for families.

September 12, 2026 / 10 sources

Educational diagram of pancreatic insulin-producing beta cells.

Research Watch

Type 1 diabetes research watch: recent papers and DOI records worth sorting

A daily research brief that separates literature discovery from clinical meaning, so promising headlines do not get mistaken for proven care changes.

September 12, 2026 / 12 sources

Diabetes awareness public health display.

Editorial Policy

How Type1Cure labels Type 1 diabetes evidence before it becomes a headline

The editorial model behind Type1Cure: rank sources by evidence strength, preserve source links, separate sponsor influence, and avoid miracle-cure language.

September 12, 2026 / 6 sources